Cost is consideration ($1,200-1,400/month projected)
Conclusions apply only to what was actually tested
Phase 3 trials have now initiated for overweight and obesity at this point, assessing CagriSema in larger numbers and for longer periods of time. References: Frias JP, et al
Key benefits include: - Quantifies bone mineral density (BMD) at clinically relevant sites (spine, hip, forearm) - Identifies individual fracture risk before clinical events - Supports evidence-based interventions such as lifestyle modification, nutrition, and pharmacotherapy - Uses minimal radiation exposure - Offers a measurable tool for monitoring treatment efficacy Proactive bone health management is essential to prevent fractures, maintain function, and improve long-term quality of life
Overall, BPC-157 is thought to act through a coordinated network of biological pathways rather than a single receptor-mediated mechanism